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Background
DNA vaccines offer several advantages over other vaccine
concepts, but poor immunogenicity in clinical use is still
a general concern. Therefore, strategies to optimize the
immunogenicity of DNA vaccines are urgently needed.
Here, we explored the efficacy of Bupivacaine on aug-
menting the immunogenicity of a DNA vaccine encoding
multiple HIV epitopes designed by our group.
Methods
The nucleotide sequence encoding 18 CD4/CD8 HIV-1 T
cell epitopes was subcloned in pVAX-1. The DNA vaccine
(pVAX-HIVBr18) or empty pVAX were used to immunize
BALB/c mice, alone or in the presence of Bupivacaine (a
local anaesthetic with adjuvant properties). T cell
responses were assessed by IFN-gamma and IL-2 ELIS-
POT, polyfunctional flow cytometry, Cytometric bead
array on culture supernatants, and CFSE proliferation.
Breadth of immune response was evaluated using ELIS-
POT assay against individual peptides.
Results
Coadministration of pVAXHIVBr18 with Bupivacaine was
able to induce higher numbers of IFN-gamma secreting
cells (ELISPOT) as well as a marked increase in IFN-
gamma and TNF-α secretion against pooled HIV peptides
when compared to pVAXHIVBr18 alone. Additionally,
coadministration with Bupivacaine induced an increase of
trifunctional (IFN+/IL-2+/TNF+) CD4 T cells compared to
the DNA vaccine alone. Also, coadministration of DNA
vaccine with Bupivacaine increased IFN-gamma+/IL-2+
effector memory CD4 T cells and IFN-gamma producing
effector memory CD8 T cells. Proliferative capacity of anti-
gen-specific CD8 T cells was improved by Bupivacaine
coadministration, as compared to DNA vaccine alone.
This adjuvanted formulation induced multiepitopic
responses with similar breadth as DNA alone.
Conclusion
Our data suggest that Bupivacaine can increase the magni-
tude of cytokine-producing effector memory CD4+ and
CD8+ T cells, as well as increasing polyfunctional cytokine
production of CD4+ T cells, and increase proliferation of
CD8+ T cells. This may have an impact in the clinical use
of DNA vaccines.
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